Abstract
Corticosteroids are first-line therapies for the treatment of many inflammatory dermatoses, including atopic dermatitis, contact dermatitis, psoriasis and seborrheic dermatitis. Desonide, a low-potency corticosteroid, has been formulated in a moisturizing hydrogel that has been US FDA approved for mild-to-moderate atopic dermatitis in patients as young as 3 months of age. This new formulation represents a safe and effective option for atopic dermatitis patients and provides the benefits of a novel hydrogel vehicle that is both a well-tolerated and a cosmetically elegant alternative to traditional vehicles.
Financial & competing interests disclosure
AA Hebert is a researcher, lecturer and consultant for SkinMedica. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.